Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.30 |
| ▸ | FEN1 | P39748 | 2/20 | 0.30 |
| ▸ | WNT1 | P04628 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410653 | 0.81 | KMO (0.36) | DYRK1AALOX5APFEN1 | |
| SCHEMBL5405481 | 0.73 | MAOA (0.34) | PFKFB3DYRK1APDE10AMAPK14MAOA | |
| SCHEMBL5420842 | 0.71 | NPC1 (0.39) | MAPK14LTB4RALOX5APFEN1 | |
| SCHEMBL5412742 | 0.70 | HSP90AA1 (0.38) | PFKFB3DYRK1APDE10AMAPK14HSD11B1 | |
| SCHEMBL5407827 | 0.68 | KMO (0.33) | DYRK1AALOX5APFEN1 | |
| SCHEMBL13443190 | 0.68 | SLC6A2 (0.38) | — | |
| SCHEMBL20910332 | 0.64 | MAPK14 (0.53) | PDE10AMAPK14 | |
| SCHEMBL5404834 | 0.62 | KMO (0.39) | MAOAMAOB | |
| SCHEMBL10268446 | 0.61 | CCR1 (0.56) | CTSAHSD11B1 | |
| SCHEMBL5423643 | 0.61 | FEN1 (0.35) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1366026-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002024663-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | PFKFB3 169/4885DYRK1A 2963/4885PDE10A 1809/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | PFKFB3 132/4885DYRK1A 3461/4885PDE10A 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.